Kennewick, WA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a pioneer in innovative cancer treatment technologies, announces the issuance of U.S. Patent No. 12,521,452 B2 by the United States Patent and Trademark Office (USPTO), titled “Radiotherapy Gel and Method of Preparing the Same.” The patent, granted on January 13, 2026, protects critical advancements in the company’s proprietary Precision Radionuclide TherapyTM (PRnT) platform, underpinning its flagship products RadioGel ® (for human ...

FDA审批状态 - FDA在30天审查期后拒绝批准Radiogel®研究性器械豁免（IDE）申请 [1] - 公司计划在10天内与FDA进行初步通话 并在数周内参与提交前会议 目标为重新提交IDE申请 [2] - Radiogel®已获得FDA突破性器械认定 并展示出卓越的治疗比率和强大的安全性数据 [2] 公司战略方向 - 公司持续致力于推动Radiogel®在美国市场的获批进程 [2] - 联系方式包括首席执行官Michael K Korenko及公司官方社交媒体渠道 [3]